Prof John Eisman
Research Level
Biography
John Eisman AO (MB BS, PhD, FRACP) is Director of Clinical Translation and Advanced Education at Garvan. From 1984 to December 2011 he was Garvan's Director of Osteoporosis and Bone Biology.
His medical and basic science training was in Sydney and Melbourne with post-doctoral studies in Madison, Wisconsin and Bern, Switzerland. Professor Eisman initiated and has run the Bone and Calcium clinic at St Vincent’s Hospital and the Dubbo Osteoporosis Epidemiology Study since their inception more than 20 years ago.
Professor Eisman was Editor-in-Chief of the Journal of Bone and Mineral Research, is a past member of the Board of the International Bone and Mineral Society and of the Council of the American Society for Bone and Mineral Research. He is a co-founder and past-President of the Australia and New Zealand Bone and Mineral Society.
Professor Eisman chaired the inaugural Australian National Health Priority Action Council’s National Arthritis and Musculoskeletal Conditions Advisory Group and co-chaired its successor, the Australian Better Arthritis and Osteoporosis Expert Advisory Committee. He is currently co-chair of the NSW Health Agency for Clinical Innovation in Musculoskeletal conditions and chair of the American Society for Bone and Mineral Research (ASBMR) International Task Force on Osteoporotic Fracture.
The focus of Professor Eisman’s research is the epidemiology and genetics of osteoporosis, encompassing population, family and twin studies as well as molecular and cellular mechanisms for gene effects. His major commitment and focus is translating osteoporosis research findings to real improvements in health care delivery to the general community through the education of patients and their doctors.
John Eisman AO (MB BS, PhD, FRACP) is Director of Clinical Translation and Advanced Education at Garvan. From 1984 to December 2011 he was Garvan's Director of Osteoporosis and Bone Biology.
His medical and basic science training was in Sydney and Melbourne with post-doctoral studies in Madison, Wisconsin and Bern, Switzerland. Professor Eisman initiated and has run the Bone and Calcium clinic at St Vincent’s Hospital and the Dubbo Osteoporosis Epidemiology Study since their inception more than 20 years ago.
Professor Eisman was Editor-in-Chief of the Journal of Bone and Mineral Research, is a past member of the Board of the International Bone and Mineral Society and of the Council of the American Society for Bone and Mineral Research. He is a co-founder and past-President of the Australia and New Zealand Bone and Mineral Society.
Professor Eisman chaired the inaugural Australian National Health Priority Action Council’s National Arthritis and Musculoskeletal Conditions Advisory Group and co-chaired its successor, the Australian Better Arthritis and Osteoporosis Expert Advisory Committee. He is currently co-chair of the NSW Health Agency for Clinical Innovation in Musculoskeletal conditions and chair of the American Society for Bone and Mineral Research (ASBMR) International Task Force on Osteoporotic Fracture.
The focus of Professor Eisman’s research is the epidemiology and genetics of osteoporosis, encompassing population, family and twin studies as well as molecular and cellular mechanisms for gene effects. His major commitment and focus is translating osteoporosis research findings to real improvements in health care delivery to the general community through the education of patients and their doctors.
Awards and Honours
1997 - Order of Australia
1995 - Sir Eric Sussman Award, Royal Australasian College of Physicians
Education
1975 - PhD, University of Melbourne - Australia
1971 - Member Royal Australian College of Physicians
1967 - Bachelor of Medicine, Bachelor of Surgery First Class Honours, Sydney University - Australia
Selected Publications
Styrkarsdottir U, Thorleifsson G, Gudjonsson SA, Sigurdsson A, Center JR, Lee SH, et al. Sequence variants in the PTCH1 gene associate with spine bone mineral density and osteoporotic fractures. Nat commun. 2016;7:10129.
Styrkarsdottir U, Thorleifsson G, Eiriksdottir B, Gudjonsson SA, Ingvarsson T, Center JR, et al. Two Rare Mutations in the COL1A2 Gene Associate With Low Bone Mineral Density and Fractures in Iceland. J Bone Miner Res. 2016;31:173-9.
Pham HM, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Contribution of Quadriceps Weakness to Fragility Fracture: A Prospective Study. J Bone Miner Res. 2016;31:208-14.
Niu T, Liu N, Yu X, Zhao M, Choi HJ, Leo PJ, et al. Identification of IDUA and WNT16 Phosphorylation-Related Non-Synonymous Polymorphisms for Bone Mineral Density in Meta-Analyses of Genome-Wide Association Studies. J Bone Miner Res. 2016;31:358-68.
Lee P, Ng C, Slattery A, Nair P, Eisman JA, Center JR. Preadmission Bisphosphonate and Mortality in Critically Ill Patients. J Clin Endocrinol Metab. 2016;101:1945-53.
Lee P, Nair P, Eisman JA, Center JR. Bone Failure in Critical Illness. Crit Care Med. 2016 Jun 28.
Bliuc D, Tran T, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Secular Changes in Postfracture Outcomes Over 2 Decades in Australia: A Time-Trend Comparison of Excess Postfracture Mortality in Two Birth Controls Over Two Decades. J Clin Endocrinol Metab. 2016;101:2475-83.
Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, et al Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature. 2015;1;526:112-7.
Yang S, Center JR, Eisman JA, Nguyen TV. Association between fat mass, lean mass, and bone loss: the Dubbo Osteoporosis Epidemiology Study. Osteoporos Int. 2015;26:1381-6.
Tran TS, Center JR, Seibel MJ, Eisman JA, Kushnir MM, Rockwood AL, Nguyen TV. Relationship between Serum Testosterone and Fracture Risk in Men: A Comparison of RIA and LC-MS/MS. Clin Chem. 2015;61:1182-90.
Tangvik RJ, Tell GS, Guttormsen AB, Eisman JA, Henriksen A, Nilsen RM, Ranhoff AH. Nutritional risk profile in a university hospital population. Clin Nutr. 2015;34:705-11.
Sogaard AJ, Holvik K, Omsland TK, Tell GS, Dahl C, Schei B, Falch JA, Eisman JA, Meyer HE. Abdominal obesity increases the risk of hip fracture. A population-based study of 43,000 women and men aged 60-79 years followed for 8 years. Cohort of Norway. J Intern Med. 2015;277:306-17.
Omsland TK, Eisman JA, Naess O, Center JR, Gjesdal CG, Tell GS, Emaus N, Meyer HE, Sogaard AJ, Holvik K, Schei B, Forsmo S, Magnus JH. Educational Inequalities in Post-Hip Fracture Mortality: A NOREPOS Study. J Bone Miner Res. 2015;30:2221-8.
Niu T, Liu N, Zhao M, Xie G, Zhang L, Li J, et al. Identification of a novel FGFRL1 MicroRNA target site polymorphism for bone mineral density in meta-analyses of genome-wide association studies. Hum Mol Genet. 2015;15;24:4710-27.
Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015;26:699-712.
Bliuc D, Nguyen ND, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Accelerated bone loss and increased post-fracture mortality in elderly women and men. Osteoporos Int. 2015;26:1331-9.
Bliuc D, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res. 2015;30:637-46.
Tran B, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between fat-mass-and-obesity-associated (FTO) gene and hip fracture susceptibility. Clin Endocrinol (Oxf). 2014;81:210-7.
Tangvik RJ, Tell GS, Eisman JA, Guttormsen AB, Henriksen A, Nilsen RM, Oyen J, Ranhoff AH. The nutritional strategy: four questions predict morbidity, mortality and health care costs. Clin Nutr. 2014;33:634-41.
Omsland TK, Emaus N, Tell GS, Magnus JH, Ahmed LA, Holvik K, Center J, Forsmo S, Gjesdal CG, Schei B, Vestergaard P, Eisman JA, Falch JA, Tverdal A, Sogaard AJ, Meyer HE. Mortality following the first hip fracture in Norwegian women and men (1999-2008). A NOREPOS study. Bone. 2014;63:81-6.
Moayyeri A, Hsu YH, Karasik D, Estrada K, Xiao SM, Nielson C, et al. Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Hum Mol Genet. 2014;1;23:3054-68.
Kon E, Filardo G, Robinson D, Eisman JA, Levy A, Zaslav K, Shani J, Altschuler N. Osteochondral regeneration using a novel aragonite-hyaluronate bi-phasic scaffold in a goat model. Knee Surg Sports Traumatol Arthrosc. 2014;22:1452-64.
Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B, Eisman JA, Geusens PP, Brink PR. Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am. 2014;19;96:e29.
Eisman JA, Bouillon R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. Bonekey Rep. 2014;3:499.
Chan MY, Frost SA, Center JR, Eisman JA, Nguyen TV. Relationship between body mass index and fracture risk is mediated by bone mineral density. J Bone Miner Res. 2014;29:2327-35.
Bliuc D, Nguyen TV, Eisman JA, Center JR. The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab. 2014;99:415-23.
Ahmed LA, Nguyen ND, Bjornerem A, Joakimsen RM, Jorgensen L, Stormer J, Bliuc D, Center JR, Eisman JA, Nguyen TV, Emaus N. External validation of the Garvan nomograms for predicting absolute fracture risk: the Tromso study. PloS one. 2014;9:e107695.
Zhang L, Choi HJ, Estrada K, Leo PJ, Li J, Pei YF, et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet. 2014;1;23:1923-33.
Wong IP, Nguyen AD, Khor EC, Enriquez RF, Eisman JA, Sainsbury A, et al. Neuropeptide Y is a critical modulator of leptin's regulation of cortical bone. J Bone Miner Res. 2013 28:886-98.
van Geel TA, Eisman JA, Geusens PP, van den Bergh JP, Center JR, Dinant GJ. The utility of absolute risk prediction using FRAX(R) and Garvan Fracture Risk Calculator in daily practice. Maturitas. 2014;77:174-9.
Styrkarsdottir U, Thorleifsson G, Sulem P, Gudbjartsson DF, Sigurdsson A, Jonasdottir A, et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature. 2013 497:517-20.
Nair P, Lee P, Reynolds C, Nguyen ND, Myburgh J, Eisman JA, et al. Significant perturbation of vitamin D-parathyroid-calcium axis and adverse clinical outcomes in critically ill patients. Intensive Care Med. 2013 39:267-74.
Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E; for the ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012 27:2039-46.
Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011 96:1006-14.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low trauma osteoporotic fracture and subsequent fracture in men and women. J Amer Med Assoc. 2009 301:513-21.
Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. Multiple genetic loci for bone mineral density and fractures, New Engl J Med. 2008 358:2355-65.
Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008 19:1431-44.
Lundberg P, Allison SJ, Lee N, Baldock PA, Brouard N, Rost S, Enriquez R, Sainsbury A, Lamghari M, Simmons P, Eisman JA, Gardiner EM, Herzog H. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1-receptor expression. J Biol Chem 2007 282:19082-91.
Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, White CP, Sunn KL, Morrison NA, Walsh WR, Eisman JA. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J. 2000; 14:1908-16.
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet. 1999 353:878-82.
Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA. 1998 95:10529-34.
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994 367:284-7. Erratum in: Nature 1997 387:106.
Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman JA. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med. 1993 328:1747-52.
Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. J Clin Invest. 1987; 80:706-10.
Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA. 1,25-dihydroxyvitamin D responsive element and glucocorticoid repression in the osteocalcin gene. Science. 1989 246:1158-61.
Frampton RJ, Omond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 1983 43:4443-7.
Eisman JA, Suva LJ, Sher E, Pearce PJ, Funder JW, Martin TJ. Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer. Cancer Res. 1981 41:5121-4.
Eisman JA, Martin TJ, MacIntyre I, Moseley JM. 1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet. 1979; 22-29;2(8156-8157):1335-6.
Eisman JA, Hamstra AJ, Kream BE, DeLuca HF. 1,25-Dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. Science. 1976 193:1021-3.
Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987 47:21-5.
Bilezikian JP, Canfield RE, Jacobs TP, Polay JS, D'Adamo AP, Eisman JA, DeLuca HF. Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects. N Engl J Med. 1978 299:437-41.
